Sight Sciences (NASDAQ:SGHT) Insider Sells $73,390.70 in Stock

by · The Markets Daily

Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) insider Jeremy Hayden sold 9,385 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $7.82, for a total transaction of $73,390.70. Following the completion of the sale, the insider owned 247,205 shares of the company’s stock, valued at $1,933,143.10. This trade represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Sight Sciences Stock Up 1.2%

SGHT stock opened at $7.53 on Friday. Sight Sciences, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $9.24. The company has a market capitalization of $398.11 million, a price-to-earnings ratio of -8.37 and a beta of 2.42. The business’s 50 day moving average price is $7.62 and its two-hundred day moving average price is $5.17. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last released its earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. The firm had revenue of $12.54 million during the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. As a group, analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. UBS Group lifted their target price on shares of Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Raymond James Financial set a $9.00 price objective on Sight Sciences in a research report on Monday. Finally, Wall Street Zen upgraded Sight Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.30.

View Our Latest Report on SGHT

Hedge Funds Weigh In On Sight Sciences

A number of hedge funds have recently added to or reduced their stakes in SGHT. KCK LTD. purchased a new stake in Sight Sciences during the 2nd quarter valued at $18,069,000. Long Focus Capital Management LLC lifted its holdings in shares of Sight Sciences by 1.3% during the third quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock valued at $10,985,000 after purchasing an additional 41,797 shares in the last quarter. Vanguard Group Inc. increased its holdings in Sight Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock worth $6,559,000 after buying an additional 102,609 shares in the last quarter. Americana Partners LLC raised its position in Sight Sciences by 42.4% in the 3rd quarter. Americana Partners LLC now owns 1,229,819 shares of the company’s stock worth $4,231,000 after buying an additional 365,901 shares during the last quarter. Finally, B Group Inc. raised its position in Sight Sciences by 11.6% in the 2nd quarter. B Group Inc. now owns 930,000 shares of the company’s stock worth $3,841,000 after buying an additional 96,400 shares during the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.

Featured Stories